SCHEMBL5650806

SCHEMBL5650806

CCOc1cc(C(=O)NN2CCCCC2)ccc1-c1nc2cc3ccccc3cc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.46
SIRT1 Q96EB6 1/20 0.46
POLB P06746 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HTT P42858 1/20 0.45
HPSE Q9Y251 3/20 0.43
MAPT P10636 5/20 0.42
TP53 P04637 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
GCK P35557 1/20 0.41
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653237 0.90 HDAC6 (0.46) SMN1; SMN2MEN1KMT2AHTTHPSE
SCHEMBL5648605 0.89 RHEB (0.45) SIRT2SIRT1POLBSMN1; SMN2MEN1
SCHEMBL5648702 0.88 SIRT2 (0.47) SIRT2SIRT1POLBSMN1; SMN2MEN1
SCHEMBL5650184 0.87 HPSE (0.45) SIRT2SIRT1POLBSMN1; SMN2MEN1
SCHEMBL5652578 0.86 SIRT2 (0.42) SIRT2SIRT1POLBSMN1; SMN2MEN1
SCHEMBL5652908 0.85 HTT (0.43) SIRT2SIRT1MEN1KMT2AHTT
SCHEMBL5652493 0.84 SIRT2 (0.47) SIRT2SIRT1POLBSMN1; SMN2MEN1
SCHEMBL5652807 0.84 PDE5A (0.53) POLBSMN1; SMN2MEN1KMT2AHTT
SCHEMBL5652928 0.83 HPSE (0.53) SIRT2SIRT1POLBSMN1; SMN2MEN1
SCHEMBL5651542 0.83 KMT2A (0.42) SIRT2SIRT1POLBSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 SIRT2 360/4885SIRT1 300/4885POLB 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.